> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Ojjaara
- URL: https://www.fdaweb.com/regulatory-review-period-for-ojjaara/
- Published: 2024-09-24T12:00:00.000Z
- Updated: 2026-09-14T14:42:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157841

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for GlaxoSmithKline’s Ojjaara (momelotinib), indicated for treating intermediate or high-risk myelofibrosis in adults with anemia. The regulatory review period is 5,127 days, of which 4,670 days occurred during the testing phase and 457 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-09-24/pdf/2024-21844.pdf?ref=fdaweb.com).